Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.

The Biogen/Eisai drug may have a disease-modifying impact on Alzheimer’s progression but the lack of published evidence is still causing prescriber reluctance and hampering reimbursement decisions.

India’s draft policy to catalyze R&D and innovation seeks to create a “regulatory bias” towards innovation and aims to cut approval timelines sharply, among a raft of other proposals that include enabling differential pricing for “innovation with therapeutic benefits.” The Pink Sheet explores multiple nuances of the plan with industry experts.

While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.